Overview

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Status:
Enrolling by invitation
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
UCB Biopharma SRL